Wet AMD
46 programs · 45 companies
Programs
46
Companies
45
Trials
35
MOAs
31
EGFRiAuroraAiHPK1iCDK2iIL-23iKIF18AiKRASG12DiGLP-1/GIPPD-L1iBTKi
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Phase 2 | KIF18A | ||
| TAK-5300 | Phase 1 | SMN2 | ||
| BII-5240 | Phase 2/3 | MALT1 | ||
| ARG-6988 | Preclinical | AuroraA | ||
| Tirasotorasib | Phase 1 | CFTR | ||
| GPC-2382 | Preclinical | TROP-2 | ||
| ALM-8546 | Phase 1/2 | MDM2 | ||
| TER-5062 | Phase 2/3 | Tau | ||
| CSL-8153 | Approved | CD3 | ||
| HCM-8303 | Phase 2 | GIP-R | ||
| Fixaderotide | Phase 2 | CFTR | ||
| PEK-IIT-646 | Phase 1 | APOC3 | ||
| ISO-9327 | Phase 1 | KRASG12C | ||
| Tixasotorasib | Approved | VEGF | ||
| Motavorutinib | NDA/BLA | PRMT5 | ||
| IPS-8044 | Preclinical | FXIa | ||
| Zorinaritide | NDA/BLA | PSMA | ||
| IMM-5415 | Preclinical | PD-1 | ||
| HRT-9539 | NDA/BLA | LAG-3 | ||
| Elrasotorasib | NDA/BLA | WRN | ||
| KNS-8287 | Phase 2 | Nectin-4 | ||
| Tixazasiran | Phase 1 | MET | ||
| Elrazanubrutinib | NDA/BLA | Menin | ||
| Kemanesiran | Phase 1 | GLP-1R | ||
| NVE-9277 | Phase 2 | IL-17A | ||
| Cevimavacamten | Phase 1 | APOC3 | ||
| Daramavacamten | Preclinical | CFTR | ||
| HIK-6819 | Preclinical | TIM-3 | ||
| Polarasimod | Approved | KIF18A | ||
| Capiderotide | Phase 2 | Nectin-4 | ||
| Teranesiran | Phase 2 | IL-17A | ||
| PLU-3424 | Phase 2 | SHP2 | ||
| Semalemzoparlimab | Phase 1/2 | CD47 | ||
| Zanutinib | Approved | LAG-3 | ||
| Motamavacamten | Phase 3 | BTK | ||
| Tiranesiran | Preclinical | MALT1 | ||
| Daranesiran | Preclinical | IL-23 | ||
| Elraosocimab | Phase 3 | Cl18.2 | ||
| BIO-IIT-528 | Phase 2 | IL-17A | ||
| AMO-1639 | Phase 2 | CD38 | ||
| INS-IIT-499 | Preclinical | TROP-2 | ||
| Talazanubrutinib | Phase 1/2 | EGFR | ||
| RIC-2161 | Phase 2/3 | ALK | ||
| Kematenlimab | Phase 2/3 | VEGF | ||
| Daranaritide | Phase 2/3 | SMN2 | ||
| Riluzumab | Approved | SHP2 |
Trials (35)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT05943465 | Niranesiran | Phase 2 | Not yet recr... |
| NCT05700724 | BII-5240 | Phase 2/3 | Not yet recr... |
| NCT03727938 | ARG-6988 | Preclinical | Completed |
| NCT06736380 | GPC-2382 | Preclinical | Not yet recr... |
| NCT06904770 | ALM-8546 | Phase 1/2 | Recruiting |
| NCT05414436 | TER-5062 | Phase 2/3 | Terminated |
| NCT05167480 | TER-5062 | Phase 2/3 | Active |
| NCT04724095 | HCM-8303 | Phase 2 | Completed |
| NCT05598328 | HCM-8303 | Phase 2 | Recruiting |
| NCT04920501 | Fixaderotide | Phase 2 | Not yet recr... |
| NCT03045690 | PEK-IIT-646 | Phase 1 | Active |
| NCT03467850 | Tixasotorasib | Approved | Completed |
| NCT06561627 | Tixasotorasib | Approved | Not yet recr... |
| NCT06890104 | Motavorutinib | NDA/BLA | Not yet recr... |
| NCT07627218 | Motavorutinib | NDA/BLA | Recruiting |
| NCT05893585 | Zorinaritide | NDA/BLA | Not yet recr... |
| NCT07879502 | HRT-9539 | NDA/BLA | Recruiting |
| NCT03539333 | Elrasotorasib | NDA/BLA | Active |
| NCT04592983 | KNS-8287 | Phase 2 | Terminated |
| NCT07211223 | NVE-9277 | Phase 2 | Recruiting |